LFST (LifeStance Health Group) YoY EBITDA Growth: 125.64% (As of Mar. 2026)


LFST LifeStance Health Group Inc LFST
56 GF Score
Price $10.93
GF Value $8.26
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is LifeStance Health Group YoY EBITDA Growth?

LifeStance Health Group LFST -0.59% 56 YoY EBITDA Growth is 125.64% as of Mar. 2026. GuruFocus rates LFST with a GF Score™ of 56/100 and a GF Value™ of $8.26 (Significantly Overvalued). The stock has 5 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. LifeStance Health Group's YoY EBITDA Growth for the quarter that ended in Mar. 2026 was 125.64%.

LifeStance Health Group's EBITDA per Share for the three months ended in Mar. 2026 was $0.09.

LifeStance Health Group YoY EBITDA Growth Related Terms

LifeStance Health Group YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for LifeStance Health Group's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LifeStance Health Group YoY EBITDA Growth Chart

LifeStance Health Group Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
YoY EBITDA Growth
Get a 7-Day Free Trial 0.00 44.88 29.21 136.71 91.43

LifeStance Health Group Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 85.71 460.00 35.00 92.50 125.64
LFST
56GF Score
LifeStance Health Group Inc LFST
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

LifeStance Health Group YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

LifeStance Health Group's YoY EBITDA Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (A: Dec. 2025 )
=(EBITDA per Share (A: Dec. 2025 )-EBITDA per Share (A: Dec. 2024 ))/ | EBITDA per Share (A: Dec. 2024 ) |
=(0.201-0.105)/ | 0.105 |
=91.43 %

LifeStance Health Group's YoY EBITDA Growth for the quarter that ended in Mar. 2026 is calculated as:

YoY EBITDA Growth (Q: Mar. 2026 )
=(EBITDA per Share (Q: Mar. 2026 )-EBITDA per Share (Q: Mar. 2025 )) / | EBITDA per Share (Q: Mar. 2025 )) |
=(0.088-0.039)/ | 0.039 |
=125.64 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 125.64% mean?
LifeStance Health Group (LFST) has a YoY EBITDA Growth of 125.64% as of Mar. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for LifeStance Health Group and its competitors.
Is LifeStance Health Group's YoY EBITDA Growth too high?
LifeStance Health Group's current YoY EBITDA Growth is 125.64%. Overall, LifeStance Health Group has a GF Score™ of 56/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does LifeStance Health Group's YoY EBITDA Growth compare to CON and BKD?
LifeStance Health Group's YoY EBITDA Growth of 125.64% can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Healthcare Providers & Services company?
A good YoY EBITDA Growth depends on the Healthcare Providers & Services industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for LifeStance Health Group and its competitors. LifeStance Health Group's current YoY EBITDA Growth is 125.64%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LifeStance Health Group stock overvalued right now?
Based on GuruFocus' analysis, LifeStance Health Group (LFST) is currently considered Significantly Overvalued. The stock's GF Value™ is $8.26, compared to a current price of $10.93 — trading 32.3% above its estimated fair value. The current YoY EBITDA Growth is 125.64%. LifeStance Health Group's overall GF Score™ is 56/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For LifeStance Health Group (LFST), the current YoY EBITDA Growth is 125.64% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is LifeStance Health Group (LFST) Overvalued in 2026?

Based on GuruFocus' analysis, LifeStance Health Group stock appears to be overvalued. The current stock price of $10.93 is trading 32.3% above its estimated GF Value™ of $8.26. GuruFocus considers LifeStance Health Group to be Significantly Overvalued.

Key valuation signals for LFST:

  • YoY EBITDA Growth: 125.64%
  • GF Value™: $8.26 vs. price of $10.93 (32.3% above fair value)
  • GF Score™: 56/100 with 5 warning signs

No single metric tells the full story. See the LFST stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

LifeStance Health Group Business Description

Address 4800 North Scottsdale Road, Suite 2500, Scottsdale, AZ, USA, 85251
LifeStance Health Group Inc is a mental healthcare company that operates as a provider of outpatient mental health services, spanning psychiatric evaluations and treatment, psychological and neuropsychological testing, and individual, family, and group therapy. It treats a broad range of mental health conditions, including anxiety, depression, bipolar disorder, eating disorders, psychotic disorders, and post-traumatic stress disorder, using evidence-based approaches to ensure effective treatment. The group has a single operating and reportable segment of mental health services.
56GF Score

Get the complete analysis for LFST

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.93
Price
$8.26
GF Value